Each tablet contains Bethanechol chloride, USP 25 mg.
Uriflow (Bethanechol chloride), a cholinergic agent, is a synthetic ester that is structurally and pharmacologically related to acetylcholine. It used to improve emptying of the bladder.
Pharmacology: Bethanechol chloride acts principally by producing the effects of stimulation of the parasympathetic nervous system. It increases the tone of the detrusor urinae muscle, usually producing a contraction sufficiently strong to initiate micturition and empty the bladder. It stimulates gastric motility, increases gastric tone, and often restores impaired rhythmic peristalsis. Stimulation of the parasympathetic nervous system releases acetylcholine at the nerve endings. When spontaneous stimulation is reduced and therapeutic intervention is required, acetylcholine can be given, but it is rapidly hydrolyzed by cholinesterase, and its effects are transient. Bethanechol chloride is not destroyed by cholinesterase and its effects are more prolonged than those of acetylcholine. Effects on the GI and urinary tracts sometimes appear within 30 minutes after oral administration of bethanechol chloride, but more often 60-90 minutes are required to reach maximum effectiveness. Following oral administration, the usual duration of action of bethanechol is one hour, although large doses (300-400 mg) have been reported to produce effects for up to six hours.
For treatments of acute postoperative and postpartum nonobstructive (function) urinary retention and for neurogenic atony of the urinary bladder with retention.
The usual adult dosage is 10 to 50 mg three or four times a day. The minimum effective dose is determined by giving 5 or 10 mg initially and repeating the same amount at hourly intervals until satisfactory response occurs or until a maximum of 50 mg has been given. The effects of the drug sometimes appear within 30 minutes and usually within 60 to 90 minutes. They persist for about an hour.
Hypersensitivity to Uriflow tablets, hyperthyroidism, peptic ulcer, latent or active bronchial asthma, pronounced bradycardia or hypotension, vasomotor instability, coronary artery disease, epilepsy, and parkinsonism.
Uriflow should not be employed when the strength or integrity of the gastrointestinal or bladder wall is in question, or in the presence of mechanical obstruction; when increased muscular activity of the gastrointestinal tract or urinary bladder might prove harmful, as following recent urinary bladder surgery, gastrointestinal resection and anastomosis, or when there is possible gastrointestinal obstruction; in bladder neck obstruction, spastic gastrointestinal disturbances, acute inflammatory lesions of the gastrointestinal tract, or peritonitis; or in marked vagotonia.
In urinary retention, if the sphincter fails to relax as Uriflow contracts the bladder, urine may be forced up the ureter into the kidney pelvis. If there is bacteriuria, this may cause reflux infection. Uriflow tablets should preferably be taken one hour or two hours after meals to avoid nausea or vomiting.
Dizziness, lightheadedness or fainting may occur, especially when getting up from a lying or sitting position.
Pregnancy: Pregnancy category C: If the patient plans on becoming pregnant, discuss with the doctor the benefits and risks of using this medicine during pregnancy. It is unknown if this medicine is excreted in breast milk.
Adverse reactions are rare following oral administration of bethanechol, but are more common following subcutaneous injection. Adverse reactions are more likely to occur when dosage is increased.
The following adverse reactions have been observed:
Body as a Whole: malaise.
Digestive: abdominal cramps or discomfort, colicky pain, nausea and belching, diarrhea, borborygmi, salivation.
Renal: urinary urgency.
Nervous System: headache.
Cardiovascular: a fall in blood pressure with reflex tachycardia, vasomotor response.
Skin: flushing producing a feeling of warmth, sensation of heat about the face, sweating.
Respiratory: bronchial constriction, asthmatic attacks.
Special Senses: lacrimation, miosis.
Special care is required if drug is given to patients receiving ganglion blocking compounds because a critical fall in blood pressure may occur. Usually, severe abdominal symptoms appear before there is such a fall in the blood pressure.
Store at temperature not exceeding 25°C.
Protect from light.
N07AB02 - bethanechol ; Belongs to the class of choline esters. Used as parasympathomimetics.
Uriflow tab 25 mg
100's (P9,175/pack)
Sign Out
